HUTCHMED (China) logo
HUTCHMED (China)
HCM | NASDAQ
Chart Builder DCF Calculator
$14.73
-$0.17 (-1.14%)
At close: Nov 16, 2026, 4:00 PM ET
$14.73
$0.00 (0.00%)
After-hours: Nov 16, 2026, 4:10 PM ET

HUTCHMED (China) Company Profile

Company profile explained

Company Profile

HUTCHMED (China) Limited is a biopharmaceutical firm dedicated to the discovery, advancement, and marketing of innovative targeted and immune-based treatments for various cancers and immune-related disorders. Its operations are divided into two main areas: Oncology/Immunology and a segment encompassing Other Ventures. The company's reach extends from Hong Kong globally. Among its pipeline, HUTCHMED is developing Savolitinib, an inhibitor targeting non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC). Another key therapeutic, Fruquintinib, is an inhibitor being investigated for its efficacy in CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and a range of other gastrointestinal and solid tumors. Furthermore, the company's portfolio includes Surufatinib, an inhibitor applicable to numerous conditions such as neuroendocrine tumors (NETs - both pancreatic and non-pancreatic), biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, gastric cancer (GC), thyroid cancer, endometrial cancer (EMC), NSCLC, and general solid tumors. HMPL-523, a spleen tyrosine kinase inhibitor, is designed to treat hematological cancers and specific chronic immune conditions, while HMPL-689 targets the isoform PI3Kd (phosphoinositide 3'-kinase delta). Additional compounds in development include Tazemetostat, an EZH2 inhibitor indicated for specific epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor showing promise for hematological malignancies, gliomas, and solid tumors; HMPL-760, which functions as a Bruton's tyrosine kinase inhibitor; and HMPL-453, an inhibitor aimed at intrahepatic cholangiocarcinoma. The pipeline also features HMPL-295 for solid tumors, HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors, alongside Epitinib (HMPL-813) and Theliatinib (HMPL-309), both of which act as inhibitors. HUTCHMED maintains strategic collaboration agreements with a number of partners, including AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The entity, established in 2000 and headquartered in Central, Hong Kong, was previously identified as Hutchison China MediTech Limited before officially adopting its current name, HUTCHMED (China) Limited, in May 2021.

Key Executives

Name Position
Chig Fung Cheng Acting Chief Executive Officer, Chief Financial Officer & Executive Director
Weiguo Su Chief Executive Officer, Chief Scientific Officer & Executive Director (Leave of Absence)
Charles George Rupert Nixon Group General Counsel
David Ng Head of Investor Relations & Capital Strategies
Kin Hung Lee Senior Vice President of Corporate Management & Communications
Qingmei Wang Executive Vice President of Business Development & Strategic Alliances
Selina Zhang Senior Vice President of Global Human Resources
Thomas Fu Senior Vice President of Global Quality
Xinhui Hu Executive Vice President & Chief Technical Officer
Yiling Cui Executive Vice President & Head of Operations

Latest SEC Filings

Date Type Title
Oct 29, 2026 6-K Filing
Oct 27, 2026 6-K Filing
Oct 26, 2026 6-K Filing
Oct 21, 2026 6-K Filing
Sep 29, 2026 6-K Filing
Sep 29, 2026 6-K Filing
Sep 24, 2026 6-K Filing
Sep 03, 2026 6-K Filing
Aug 31, 2026 6-K Filing
Aug 28, 2026 6-K Filing
View All SEC Filings ➞
HUTCHMED (China)
HUTCHMED (China) logo
Country Hong Kong SAR China
IPO Date Mar 16, 2016
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 1,796
CEO Chig Fung Cheng

Contact Details

Cheung Kong Center Hong Kong Hong Kong SAR China

Stock Details

Ticker Symbol HCM
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001648257
CUSIP Number 44842L103
ISIN Number US44842L1035
SIC Code 2834

Recent News

More News ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.